Ovarian cancer biomarkers: Current state and future implications from high-throughput technologies

Advances in Clinical Chemistry

Volumn 66, Issue , 2014, Pages 25-77

  Leung, Felix ^a,b   Diamandis, Eleftherios P ^a,b,c   Kulasingam, Vathany ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Discovery; High throughput technologies; Mass spectrometry; Next generation sequencing; Ovarian cancer; Serum biomarkers; Validation

Indexed keywords

CA 125 ANTIGEN; DNA; PROTEIN; TUMOR MARKER; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1; VTCN1 PROTEIN, HUMAN; WFDC2 PROTEIN, HUMAN;

ARTICLE; BLOOD; CANCER STAGING; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; METHODOLOGY; OVARY TUMOR; PROTEOMICS;

CA-125 ANTIGEN; DNA, NEOPLASM; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROTEINS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL; V-SET DOMAIN-CONTAINING T-CELL ACTIVATION INHIBITOR 1;

EID: 84906100584     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-801401-1.00002-5     Document Type: Chapter

References (221)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2013, 63:11-30.
2. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med. 2004, 351:2519-2529.
3. Martin V.R. Ovarian cancer. Semin. Oncol. Nurs. 2002, 18:174-183.
4. Partridge E.E., Barnes M.N. Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J. Clin. 1999, 49:297-320.
5. Leung F., Diamandis E.P., Kulasingam V. From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade. Biomark. Med. 2012, 6:613-625.
6. Hayes D.F., Bast R.C., Desch C.E., Fritsche H., Kemeny N.E., Jessup J.M., et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl. Cancer Inst. 1996, 88:1456-1466.
7. Isonishi S. Biomarker in gynecologic malignancies. Gan To Kagaku Ryoho 2004, 31:1003-1007.
8. Vaughan S., Coward J.I., Bast R.C., Berchuck A., Berek J.S., Brenton J.D., et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 2011, 11:719-725.
9. Fathalla M.F. Incessant ovulation-a factor in ovarian neoplasia?. Lancet 1971, 2:163.
10. Feeley K.M., Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001, 38:87-95.
11. Gwinn M.L., Lee N.C., Rhodes P.H., Layde P.M., Rubin G.L. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J. Clin. Epidemiol. 1990, 43:559-568.
12. Nasca P.C., Greenwald P., Chorost S., Richart R., Caputo T. An epidemiologic case-control study of ovarian cancer and reproductive factors. Am. J. Epidemiol. 1984, 119:705-713.
13. Whittemore A.S. Characteristics relating to ovarian cancer risk: implications for prevention and detection. Gynecol. Oncol. 1994, 55:S15-S19.
14. Risch H.A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J. Natl. Cancer Inst. 1998, 90:1774-1786.
15. Schildkraut J.M., Schwingl P.J., Bastos E., Evanoff A., Hughes C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet. Gynecol. 1996, 88:554-559.
16. Cramer D.W., Welch W.R. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J. Natl. Cancer Inst. 1983, 71:717-721.
17. Ness R.B., Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J. Natl. Cancer Inst. 1999, 91:1459-1467.
18. Ozols R.F., Bookman M.A., Connolly D.C., Daly M.B., Godwin A.K., Schilder R.J., et al. Focus on epithelial ovarian cancer. Cancer Cell 2004, 5:19-24.
19. Roland I.H., Yang W.L., Yang D.H., Daly M.B., Ozols R.F., Hamilton T.C., et al. Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies. Cancer 2003, 98:2607-2623.
20. Akhmedkhanov A., Toniolo P., Zeleniuch-Jacquotte A., Kato I., Koenig K.L., Shore R.E. Aspirin and epithelial ovarian cancer. Prev. Med. 2001, 33:682-687.
21. Kupryjanczyk J., Thor A.D., Beauchamp R., Merritt V., Edgerton S.M., Bell D.A., Yandell D.W. p53 gene mutations and protein accumulation in human ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:4961-4965.
22. Vang R., Shih I., Kurman R.J. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology 2013, 62:44-58.
23. Auersperg N., Edelson M.I., Mok S.C., Johnson S.W., Hamilton T.C. The biology of ovarian cancer. Semin. Oncol. 1998, 25:281-304.
24. Herbst A.L. The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease. Am. J. Obstet. Gynecol. 1994, 170:1099-1105.
25. Williams T.I., Toups K.L., Saggese D.A., Kalli K.R., Cliby W.A., Muddiman D.C. Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. J. Proteome Res. 2007, 6:2936-2962.
26. Slotman B.J., Rao B.R. Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. Anticancer Res. 1988, 8:417-434.
27. Gurung A., Hung T., Morin J., Gilks C.B. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Histopathology 2013, 62:59-70.
28. Hwang H., Quenneville L., Yaziji H., Gown A.M. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl. Immunohistochem. Mol. Morphol. 2004, 12:122-126.
29. Teneriello M.G., Ebina M., Linnoila R.I., Henry M., Nash J.D., Park R.C., Birrer M.J. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 1993, 53:3103-3108.
30. Arai M., Utsunomiya J., Miki Y. Familial breast and ovarian cancers. Int. J. Clin. Oncol. 2004, 9:270-282.
31. Bell K.A., Kurman R.J. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am. J. Surg. Pathol. 2000, 24:1465-1479.
32. Roth L.M., Emerson R.E., Ulbright T.M. Ovarian endometrioid tumors of low malignant potential: a clinicopathologic study of 30 cases with comparison to well-differentiated endometrioid adenocarcinoma. Am. J. Surg. Pathol. 2003, 27:1253-1259.
33. Geisler J.P., Buller E., Manahan K.J. Estrogen receptor alpha and beta expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary. Eur. J. Gynaecol. Oncol. 2008, 29:126-128.
34. Soslow R.A. Histologic subtypes of ovarian carcinoma: an overview. Int. J. Gynecol. Pathol. 2008, 27:161-174.
35. Campbell I.G., Russell S.E., Choong D.Y., Montgomery K.G., Ciavarella M.L., Hooi C.S., et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004, 64:7678-7681.
36. Obata K., Morland S.J., Watson R.H., Hitchcock A., Chenevix-Trench G., Thomas E.J., Campbell I.G. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 1998, 58:2095-2097.
37. Palacios J., Gamallo C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res. 1998, 58:1344-1347.
38. Vang R., Gown A.M., Barry T.S., Wheeler D.T., Yemelyanova A., Seidman J.D., Ronnett B.M. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am. J. Surg. Pathol. 2006, 30:1130-1139.
39. Vang R., Gown A.M., Barry T.S., Wheeler D.T., Ronnett B.M. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod. Pathol. 2006, 19:97-105.
40. Cao D., Ji H., Ronnett B.M. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int. J. Gynecol. Pathol. 2005, 24:67-72.
41. Enomoto T., Weghorst C.M., Inoue M., Tanizawa O., Rice J.M. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am. J. Pathol. 1991, 139:777-785.
42. Ichikawa Y., Nishida M., Suzuki H., Yoshida S., Tsunoda H., Kubo T., et al. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res. 1994, 54:33-35.
43. Otsuka J., Okuda T., Sekizawa A., Amemiya S., Saito H., Okai T., et al. K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma. Med. Electron Microsc. 2004, 37:188-192.
44. Sato N., Tsunoda H., Nishida M., Morishita Y., Takimoto Y., Kubo T., Noguchi M. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2000, 60:7052-7056.
45. Lawrie T.A., Medeiros L.R., Rosa D.D., da Rosa M.I., Edelweiss M.I., Stein A.T., et al. Laparoscopy versus laparotomy for FIGO stage I ovarian cancer. Cochrane Database Syst. Rev. 2013, 2. CD005344.
46. Heintz A.P., Odicino F., Maisonneuve P., Beller U., Benedet J.L., Creasman W.T., et al. Carcinoma of the ovary. J. Epidemiol. Biostat. 2001, 6:107-138.
47. Dauplat J., Hacker N.F., Nieberg R.K., Berek J.S., Rose T.P., Sagae S. Distant metastases in epithelial ovarian carcinoma. Cancer 1987, 60:1561-1566.
48. Rose P.G., Piver M.S., Tsukada Y., Lau T.S. Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer 1989, 64:1508-1513.
49. Martin V.R. Straight talk about ovarian cancer. Nursing 2005, 35:36-41.
50. Bristow R.E., Montz F.J., Lagasse L.D., Leuchter R.S., Karlan B.Y. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol. Oncol. 1999, 72:278-287.
51. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl. Cancer Inst. Monogr. 1975, 42:101-104.
52. Jaaback K., Johnson N., Lawrie T.A. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst. Rev. 2011, CD005340.
53. Bhoola S., Hoskins W.J. Diagnosis and management of epithelial ovarian cancer. Obstet. Gynecol. 2006, 107:1399-1410.
54. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol. Oncol. 1994, 55:S4-S14.
55. Curtin J.P. Management of the adnexal mass. Gynecol. Oncol. 1994, 55:S42-S46.
56. du B.A., Rochon J., Pfisterer J., Hoskins W.J. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol. Oncol. 2009, 112:422-436.
57. Vernooij F., Heintz P., Witteveen E., van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol. Oncol. 2007, 105:801-812.
58. Engelen M.J., Kos H.E., Willemse P.H., Aalders J.G., de Vries E.G., Schaapveld M., et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 2006, 106:589-598.
59. Mercado C., Zingmond D., Karlan B.Y., Sekaris E., Gross J., Maggard-Gibbons M., et al. Quality of care in advanced ovarian cancer: the importance of provider specialty. Gynecol. Oncol. 2010, 117:18-22.
60. Earle C.C., Schrag D., Neville B.A., Yabroff K.R., Topor M., Fahey A., et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J. Natl. Cancer Inst. 2006, 98:172-180.
61. Olaitan A., Weeks J., Mocroft A., Smith J., Howe K., Murdoch J. The surgical management of women with ovarian cancer in the south west of England. Br. J. Cancer 2001, 85:1824-1830.
62. Tingulstad S., Skjeldestad F.E., Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet. Gynecol. 2003, 102:499-505.
63. Carney M.E., Lancaster J.M., Ford C., Tsodikov A., Wiggins C.L. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?. Gynecol. Oncol. 2002, 84:36-42.
64. Gershenson D.M. Why American women are not receiving state-of-the-art gynecologic cancer care. Cancer J. 2001, 7:450-457.
65. Jacobs I., Oram D., Fairbanks J., Turner J., Frost C., Grudzinskas J.G. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br. J. Obstet. Gynaecol. 1990, 97:922-929.
66. Ulusoy S., Akbayir O., Numanoglu C., Ulusoy N., Odabas E., Gulkilik A. The risk of malignancy index in discrimination of adnexal masses. Int. J. Gynaecol. Obstet. 2007, 96:186-191.
67. van Trappen P.O., Rufford B.D., Mills T.D., Sohaib S.A., Webb J.A., Sahdev A., et al. Differential diagnosis of adnexal masses: risk of malignancy index, ultrasonography, magnetic resonance imaging, and radioimmunoscintigraphy. Int. J. Gynecol. Cancer 2007, 17:61-67.
68. Clarke S.E., Grimshaw R., Rittenberg P., Kieser K., Bentley J. Risk of malignancy index in the evaluation of patients with adnexal masses. J. Obstet. Gynaecol. Can. 2009, 31:440-445.
69. van den Akker P.A., Aalders A.L., Snijders M.P., Kluivers K.B., Samlal R.A., Vollebergh J.H., Massuger L.F. Evaluation of the Risk of Malignancy Index in daily clinical management of adnexal masses. Gynecol. Oncol. 2010, 116:384-388.
70. Raza A., Mould T., Wilson M., Burnell M., Bernhardt L. Increasing the effectiveness of referral of ovarian masses from cancer unit to cancer center by using a higher referral value of the risk of malignancy index. Int. J. Gynecol. Cancer 2010, 20:552-554.
71. Diamandis E.P., Fritsche H., Lilja H., Chan D.W., Schwartz M.K. Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications 2002, American Association for Clinical Chemistry, United States of America.
72. Etzioni R., Urban N., Ramsey S., McIntosh M., Schwartz S., Reid B., et al. The case for early detection. Nat. Rev. Cancer 2003, 3:243-252.
73. Diamandis E.P., Hoffman B.R., Sturgeon C.M. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the Use of Tumor Markers. Clin. Chem. 2008, 54:1935-1939.
74. Atkins D., Best D., Briss P.A., Eccles M., Falck-Ytter Y., Flottorp S., et al. Grading quality of evidence and strength of recommendations. BMJ 2004, 328:1490.
75. Hammond M.E., Taube S.E. Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. Semin. Oncol. 2002, 29:213-221.
76. Pepe M.S., Etzioni R., Feng Z., Potter J.D., Thompson M.L., Thornquist M., et al. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 2001, 93:1054-1061.
77. Pepe M.S., Feng Z., Janes H., Bossuyt P.M., Potter J.D. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J. Natl. Cancer Inst. 2008, 100:1432-1438.
78. Simpson N.K., Johnson C.C., Ogden S.L., Gamito E., Trocky N., McGuire C., et al. Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years. Control. Clin. Trials 2000, 21:356S-378S.
79. Menon U., Jacobs I. Screening for ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 2002, 16:469-482.
80. Hellstrom I., Raycraft J., Hayden-Ledbetter M., Ledbetter J.A., Schummer M., McIntosh M., et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003, 63:3695-3700.
81. Plotti F., Capriglione S., Terranova C., Montera R., Aloisi A., Damiani P., et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer?. Tumour Biol. 2012, 33:2117-2123.
82. Holcomb K., Vucetic Z., Miller M.C., Knapp R.C. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am. J. Obstet. Gynecol. 2011, 205:358.e1-358.e6.
83. Rosen D.G., Wang L., Atkinson J.N., Yu Y., Lu K.H., Diamandis E.P., et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol. Oncol. 2005, 99:267-277.
84. Sandri M.T., Bottari F., Franchi D., Boveri S., Candiani M., Ronzoni S., et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol. Oncol. 2013, 128:233-238.
85. Chan K.K., Chen C.A., Nam J.H., Ochiai K., Wilailak S., Choon A.T., et al. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Gynecol. Oncol. 2013, 128:239-244.
86. Lin J., Qin J., Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2013, 167:81-85.
87. Ferraro S., Braga F., Lanzoni M., Boracchi P., Biganzoli E.M., Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J. Clin. Pathol. 2013, 66:273-281.
88. Karlsen M.A., Sandhu N., Hogdall C., Christensen I.J., Nedergaard L., Lundvall L., et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 2012, 127:379-383.
89. Moore R.G., McMeekin D.S., Brown A.K., DiSilvestro P., Miller M.C., Allard W.J., et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 2009, 112:40-46.
90. U.S. Food and Drug Administration, 510(k) Substantial equivalence determination decision summary, 2012.
91. Miller R.W., Ueland F.R. Risk of malignancy in sonographically confirmed ovarian tumors. Clin. Obstet. Gynecol. 2012, 55:52-64.
92. Molina R., Escudero J.M., Auge J.M., Filella X., Foj L., Torne A., et al. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011, 32:1087-1095.
93. Van G.T., Veldman J., Van C.B., Cadron I., Leunen K., Amant F., et al. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. Eur. J. Cancer 2012, 48:1649-1656.
94. Zhang Z., Bast R.C., Yu Y., Li J., Sokoll L.J., Rai A.J., et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004, 64:5882-5890.
95. Fung E.T. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin. Chem. 2010, 56:327-329.
96. Bast R.C., Skates S., Lokshin A., Moore R.G. Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. Int. J. Gynecol. Cancer 2012, 22:S5-S8.
97. U.S. Food and Drug Administration, FDA news release: FDA clears a test for ovarian cancer, 2012.
98. Vermillion Inc., About OVA1, 2012.
99. Quest Diagnostics, Ovarian cancer testing: OVA1, 2012.
100. Zhang Z., Chan D.W. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol. Biomarkers Prev. 2010, 19:2995-2999.
101. Moore L.E., Pfeiffer R.M., Zhang Z., Lu K.H., Fung E.T., Bast R.C. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer 2012, 118:91-100.
102. Hogdall C., Fung E.T., Christensen I.J., Nedergaard L., Engelholm S.A., Petri A.L., et al. A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer. Gynecol. Oncol. 2011, 123:308-313.
103. Clarke C.H., Yip C., Badgwell D., Fung E.T., Coombes K.R., Zhang Z., et al. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol. Oncol. 2011, 122:548-553.
104. Muller C.Y. Doctor, should I get this new ovarian cancer test-OVA1?. Obstet. Gynecol. 2010, 116:246-247.
105. Nguyen L., Cardenas-Goicoechea S.J., Gordon P., Curtin C., Momeni M., Chuang L., Fishman D. Biomarkers for early detection of ovarian cancer. Womens Health (Lond. Engl.) 2013, 9:171-185.
106. Tang Z., Feng M., Gao W., Phung Y., Chen W., Chaudhary A., et al. A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface. Mol. Cancer Ther. 2013, 12:416-426.
107. McIntosh M.W., Drescher C., Karlan B., Scholler N., Urban N., Hellstrom K.E., Hellstrom I. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol. Oncol. 2004, 95:9-15.
108. Badgwell D., Lu Z., Cole L., Fritsche H., Atkinson E.N., Somers E., et al. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol. Oncol. 2007, 106:490-497.
109. Cramer D.W., Bast R.C., Berg C.D., Diamandis E.P., Godwin A.K., Hartge P., et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev. Res. (Phila) 2011, 4:365-374.
110. Hefler L.A., Grimm C., Ackermann S., Malur S., Radjabi-Rahat A.R., Leodolter S., et al. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res. 2003, 63:3066-3068.
111. Scambia G., Testa U., Benedetti P.P., Foti E., Martucci R., Gadducci A., et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br. J. Cancer 1995, 71:354-356.
112. Lokshin A.E., Winans M., Landsittel D., Marrangoni A.M., Velikokhatnaya L., Modugno F., et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol. Oncol. 2006, 102:244-251.
113. Edgell T., Martin-Roussety G., Barker G., Autelitano D.J., Allen D., Grant P., Rice G.E. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J. Cancer Res. Clin. Oncol. 2010, 136:1079-1088.
114. Sturgeon C.M., Duffy M.J., Stenman U.H., Lilja H., Brunner N., Chan D.W., et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. Clin. Chem. 2008, 54:e11-e79.
115. Tringler B., Liu W., Corral L., Torkko K.C., Enomoto T., Davidson S., et al. B7-H4 overexpression in ovarian tumors. Gynecol. Oncol. 2006, 100:44-52.
116. Simon I., Zhuo S., Corral L., Diamandis E.P., Sarno M.J., Wolfert R.L., Kim N.W. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res. 2006, 66:1570-1575.
117. Brakora K.A., Lee H., Yusuf R., Sullivan L., Harris A., Colella T., Seiden M.V. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol. Oncol. 2004, 93:361-365.
118. Schorge J.O., Drake R.D., Lee H., Skates S.J., Rajanbabu R., Miller D.S., et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin. Cancer Res. 2004, 10:3474-3478.
119. Nakae M., Iwamoto I., Fujino T., Maehata Y., Togami S., Yoshinaga M., Douchi T. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J. Obstet. Gynaecol. Res. 2006, 32:309-314.
120. Mor G., Visintin I., Lai Y., Zhao H., Schwartz P., Rutherford T., et al. Serum protein markers for early detection of ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:7677-7682.
121. Borgono C.A., Grass L., Soosaipillai A., Yousef G.M., Petraki C.D., Howarth D.H., et al. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res. 2003, 63:9032-9041.
122. Chang A., Yousef G.M., Jung K., Rajpert-De M.E., Diamandis E.P. Identification and molecular characterization of five novel kallikrein gene 13 (KLK13; KLK-L4) splice variants: differential expression in the human testis and testicular cancer. Anticancer Res. 2001, 21:3147-3152.
123. Diamandis E.P., Yousef G.M. Human tissue kallikreins: a family of new cancer biomarkers. Clin. Chem. 2002, 48:1198-1205.
124. Diamandis E.P., Okui A., Mitsui S., Luo L.Y., Soosaipillai A., Grass L., et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res. 2002, 62:295-300.
125. Dong Y., Kaushal A., Bui L., Chu S., Fuller P.J., Nicklin J., et al. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin. Cancer Res. 2001, 7:2363-2371.
126. Kim H., Scorilas A., Katsaros D., Yousef G.M., Massobrio M., Fracchioli S., et al. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br. J. Cancer 2001, 84:643-650.
127. Kishi T., Grass L., Soosaipillai A., Scorilas A., Harbeck N., Schmalfeldt B., et al. Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res. 2003, 63:2771-2774.
128. Kurlender L., Yousef G.M., Memari N., Robb J.D., Michael I.P., Borgono C., et al. Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer. Tumour Biol. 2004, 25:149-156.
129. Luo L.Y., Katsaros D., Scorilas A., Fracchioli S., Piccinno R., Rigault de la Longrais I.A., et al. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin. Cancer Res. 2001, 7:2372-2379.
130. Magklara A., Scorilas A., Katsaros D., Massobrio M., Yousef G.M., Fracchioli S., et al. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin. Cancer Res. 2001, 7:806-811.
131. McIntosh M.W., Liu Y., Drescher C., Urban N., Diamandis E.P. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin. Cancer Res. 2007, 13:4422-4428.
132. Obiezu C.V., Scorilas A., Katsaros D., Massobrio M., Yousef G.M., Fracchioli S., et al. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin. Cancer Res. 2001, 7:2380-2386.
133. Scorilas A., Borgono C.A., Harbeck N., Dorn J., Schmalfeldt B., Schmitt M., Diamandis E.P. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J. Clin. Oncol. 2004, 22:678-685.
134. Yousef G.M., Polymeris M.E., Yacoub G.M., Scorilas A., Soosaipillai A., Popalis C., et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res. 2003, 63:2223-2227.
135. Yousef G.M., Scorilas A., Katsaros D., Fracchioli S., Iskander L., Borgono C., et al. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J. Clin. Oncol. 2003, 21:3119-3126.
136. Yousef G.M., Polymeris M.E., Grass L., Soosaipillai A., Chan P.C., Scorilas A., et al. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res. 2003, 63:3958-3965.
137. Raspollini M.R., Amunni G., Villanucci A., Baroni G., Boddi V., Taddei G.L. Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int. J. Gynecol. Cancer 2004, 14:815-823.
138. Goodheart M.J., Ritchie J.M., Rose S.L., Fruehauf J.P., De Young B.R., Buller R.E. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin. Cancer Res. 2005, 11:3733-3742.
139. Harlozinska A., Sedlaczek P., Kulpa J., Grybos M., Wójcik E., Van Dalen A., Einarsson R. Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma. Anticancer Res. 2004, 24:1149-1157.
140. Cooper B.C., Ritchie J.M., Broghammer C.L., Coffin J., Sorosky J.I., Buller R.E., et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin. Cancer Res. 2002, 8:3193-3197.
141. Chen C.A., Cheng W.F., Lee C.N., Chen T.M., Kung C.C., Hsieh F.J., Hsieh C.Y. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol. Oncol. 1999, 74:235-240.
142. Gadducci A., Ferdeghini M., Fanucchi A., Annicchiarico C., Ciampi B., Prontera C., Genazzani A.R. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anticancer Res. 1999, 19:1401-1405.
143. Mok S.C., Chao J., Skates S., Wong K., Yiu G.K., Muto M.G., et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J. Natl. Cancer Inst. 2001, 93:1458-1464.
144. Saldova R., Struwe W.B., Wynne K., Elia G., Duffy M.J., Rudd P.M. Exploring the glycosylation of serum CA125. Int. J. Mol. Sci. 2013, 14:15636-15654.
145. O'Brien T.J., Beard J.B., Underwood L.J., Dennis R.A., Santin A.D., York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol. 2001, 22:348-366.
146. Scholler N., Urban N. CA125 in ovarian cancer. Biomark. Med. 2007, 1:513-523.
147. Scholler N., Fu N., Yang Y., Ye Z., Goodman G.E., Hellstrom K.E., Hellstrom I. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:11531-11536.
148. Robinson B.W., Creaney J., Lake R., Nowak A., Musk A.W., de Klerk N., et al. Soluble mesothelin-related protein-a blood test for mesothelioma. Lung Cancer 2005, 49(Suppl. 1):S109-S111.
149. Hassan R., Laszik Z.G., Lerner M., Raffeld M., Postier R., Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am. J. Clin. Pathol. 2005, 124:838-845.
150. Rump A., Morikawa Y., Tanaka M., Minami S., Umesaki N., Takeuchi M., Miyajima A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J. Biol. Chem. 2004, 279:9190-9198.
151. Gubbels J.A., Belisle J., Onda M., Rancourt C., Migneault M., Ho M., et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol. Cancer 2006, 5:50.
152. Scholler N., Garvik B., Hayden-Ledbetter M., Kline T., Urban N. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Lett. 2007, 247:130-136.
153. Bast R.C., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., Knapp R.C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 1981, 68:1331-1337.
154. Bast R.C., Xu F.J., Yu Y.H., Barnhill S., Zhang Z., Mills G.B. CA 125: the past and the future. Int. J. Biol. Markers 1998, 13:179-187.
155. Jacobs I., Bast R.C. The CA 125 tumour-associated antigen: a review of the literature. Hum. Reprod. 1989, 4:1-12.
156. Davelaar E.M., van Kamp G.J., Verstraeten R.A., Kenemans P. Comparison of seven immunoassays for the quantification of CA 125 antigen in serum. Clin. Chem. 1998, 44:1417-1422.
157. Montagnana M., Danese E., Giudici S., Franchi M., Guidi G.C., Plebani M., Lippi G. HE4 in ovarian cancer: from discovery to clinical application. Adv. Clin. Chem. 2011, 55:1-20.
158. Sturgeon C.M., McAllister E.J. Analysis of hCG: clinical applications and assay requirements. Ann. Clin. Biochem. 1998, 35(Pt. 4):460-491.
159. Begent R.H. The value of carcinoembryonic antigen measurement in clinical practice. Ann. Clin. Biochem. 1984, 21(Pt. 4):231-238.
160. Sari R., Yildirim B., Sevinc A., Hilmioglu F. Re. Zuckerman et al.-sensitivity of CA-125 in patients with liver cirrhosis in the presence of ascites. Am. J. Gastroenterol. 2001, 96:253-254.
161. Sevinc A., Adli M., Kalender M.E., Camci C. Benign causes of increased serum CA-125 concentration. Lancet Oncol. 2007, 8:1054-1055.
162. Sevinc A., Buyukberber S., Sari R., Kiroglu Y., Turk H.M., Ates M. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol. Oncol. 2000, 77:254-257.
163. Buys S.S., Partridge E., Black A., Johnson C.C., Lamerato L., Isaacs C., et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011, 305:2295-2303.
164. Kirchhoff C., Habben I., Ivell R., Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol. Reprod. 1991, 45:350-357.
165. Clauss A., Lilja H., Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem. J. 2002, 368:233-242.
166. McMichael J.W., Roghanian A., Jiang L., Ramage R., Sallenave J.M. The antimicrobial antiproteinase elafin binds to lipopolysaccharide and modulates macrophage responses. Am. J. Respir. Cell Mol. Biol. 2005, 32:443-452.
167. Bingle L., Singleton V., Bingle C.D. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 2002, 21:2768-2773.
168. Schummer M., Ng W.V., Bumgarner R.E., Nelson P.S., Schummer B., Bednarski D.W., et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999, 238:375-385.
169. Wang K., Gan L., Jeffery E., Gayle M., Gown A.M., Skelly M., et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 1999, 229:101-108.
170. Hough C.D., Sherman-Baust C.A., Pizer E.S., Montz F.J., Im D.D., Rosenshein N.B., et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 2000, 60:6281-6287.
171. Gilks C.B., Vanderhyden B.C., Zhu S., van de Rijn M., Longacre T.A. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol. Oncol. 2005, 96:684-694.
172. Drapkin R., von Horsten H.H., Lin Y., Mok S.C., Crum C.P., Welch W.R., Hecht J.L. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005, 65:2162-2169.
173. Furger K.A., Menon R.K., Tuck A.B., Bramwell V.H., Chambers A.F. The functional and clinical roles of osteopontin in cancer and metastasis. Curr. Mol. Med. 2001, 1:621-632.
174. Wong K.K., Cheng R.S., Mok S.C. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 2001, 30:670-675.
175. Kim J.H., Skates S.J., Uede T., Wong K.K., Schorge J.O., Feltmate C.M., et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002, 287:1671-1679.
176. Gordon J.D., Mesiano S., Zaloudek C.J., Jaffe R.B. Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. J. Clin. Endocrinol. Metab. 1996, 81:353-359.
177. Iorio M.V., Visone R., Di L.G., Donati V., Petrocca F., Casalini P., et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007, 67:8699-8707.
178. Nam E.J., Yoon H., Kim S.W., Kim H., Kim Y.T., Kim J.H., et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin. Cancer Res. 2008, 14:2690-2695.
179. Zhang Q., He X.J., Ma L.P., Li N., Yang J., Cheng Y.X., Cui H. Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues. Zhonghua Zhong Liu Za Zhi 2011, 33:885-890.
180. Resnick K.E., Alder H., Hagan J.P., Richardson D.L., Croce C.M., Cohn D.E. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 2009, 112:55-59.
181. Chen Y., Zhang L., Hao Q. Candidate microRNA biomarkers in human epithelial ovarian cancer: systematic review profiling studies and experimental validation. Cancer Cell Int. 2013, 13:86.
182. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
183. Peng D.X., Luo M., Qiu L.W., He Y.L., Wang X.F. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol. Rep. 2012, 27:1238-1244.
184. Creighton C.J., Hernandez-Herrera A., Jacobsen A., Levine D.A., Mankoo P., Schultz N., et al. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One 2012, 7:e34546.
185. Bagnoli M., De Cecco L., Granata A., Nicoletti R., Marchesi E., Alberti P., et al. Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget 2011, 2:1265-1278.
186. Fu X., Tian J., Zhang L., Chen Y., Hao Q. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett. 2012, 586:1279-1286.
187. Zhang L., Volinia S., Bonome T., Calin G.A., Greshock J., Yang N., et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7004-7009.
188. Adamczyk B., Tharmalingam T., Rudd P.M. Glycans as cancer biomarkers. Biochim. Biophys. Acta 1820, 2012:1347-1353.
189. Mechref Y., Hu Y., Garcia A., Hussein A. Identifying cancer biomarkers by mass spectrometry-based glycomics. Electrophoresis 2012, 33:1755-1767.
190. Leiserowitz G.S., Lebrilla C., Miyamoto S., An H.J., Duong H., Kirmiz C., et al. Glycomics analysis of serum: a potential new biomarker for ovarian cancer?. Int. J. Gynecol. Cancer 2008, 18:470-475.
191. Alley W.R., Vasseur J.A., Goetz J.A., Svoboda M., Mann B.F., Matei D.E., et al. N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. J. Proteome Res. 2012, 11:2282-2300.
192. Saldova R., Royle L., Radcliffe C.M., Abd Hamid U.M., Evans R., Arnold J.N., et al. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 2007, 17:1344-1356.
193. Arnold J.N., Saldova R., Hamid U.M., Rudd P.M. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics 2008, 8:3284-3293.
194. Claudino W.M., Quattrone A., Biganzoli L., Pestrin M., Bertini I., Di Leo A. Metabolomics: available results, current research projects in breast cancer, and future applications. J. Clin. Oncol. 2007, 25:2840-2846.
195. Qiu Y., Cai G., Su M., Chen T., Zheng X., Xu Y., et al. Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J. Proteome Res. 2009, 8:4844-4850.
196. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J., et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
197. Zhang T., Wu X., Ke C., Yin M., Li Z., Fan L., et al. Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. J. Proteome Res. 2013, 12:505-512.
198. Chen J., Zhou L., Zhang X., Lu X., Cao R., Xu C., Xu G. Urinary hydrophilic and hydrophobic metabolic profiling based on liquid chromatography-mass spectrometry methods: differential metabolite discovery specific to ovarian cancer. Electrophoresis 2012, 33:3361-3369.
199. Chen J., Zhang X., Cao R., Lu X., Zhao S., Fekete A., et al. Serum 27-nor-5beta-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer. J. Proteome Res. 2011, 10:2625-2632.
200. Fan L., Zhang W., Yin M., Zhang T., Wu X., Zhang H., et al. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform. Acta Oncol. 2012, 51:473-479.
201. Schmidt C.W. Metabolomics: what's happening downstream of DNA. Environ. Health Perspect. 2004, 112:A410-A415.
202. Fredolini C., Meani F., Luchini A., Zhou W., Russo P., Ross M., et al. Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. AAPS J. 2010, 12:504-518.
203. Timms J.F., Cramer R., Camuzeaux S., Tiss A., Smith C., Burford B., et al. Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer. Clin. Chem. 2010, 56:262-271.
204. Barua A., Edassery S.L., Bitterman P., Abramowicz J.S., Dirks A.L., Bahr J.M., et al. Prevalence of antitumor antibodies in laying hen model of human ovarian cancer. Int. J. Gynecol. Cancer 2009, 19:500-507.
205. Philip R., Murthy S., Krakover J., Sinnathamby G., Zerfass J., Keller L., Philip M. Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer. J. Proteome Res. 2007, 6:2509-2517.
206. Karabudak A.A., Hafner J., Shetty V., Chen S., Secord A.A., Morse M.A., Philip R. Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels. J. Cancer Res. Clin. Oncol. 2013, 139:1757-1770.
207. Forshew T., Murtaza M., Parkinson C., Gale D., Tsui D.W., Kaper F., et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl. Med. 2012, 4:136ra68.
208. Murtaza M., Dawson S.J., Tsui D.W., Gale D., Forshew T., Piskorz A.M., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497:108-112.
209. Liu J.F., Kindelberger D., Doyle C., Lowe A., Barry W.T., Matulonis U.A. Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol. Oncol. 2013, 131:352-356.
210. Swisher E.M., Wollan M., Mahtani S.M., Willner J.B., Garcia R., Goff B.A., King M.C. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am. J. Obstet. Gynecol. 2005, 193:662-667.
211. Dobrzycka B., Terlikowski S.J., Kinalski M., Kowalczuk O., Niklinska W., Chyczewski L. Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers. Ann. Oncol. 2011, 22:1133-1140.
212. Kamat A.A., Sood A.K., Dang D., Gershenson D.M., Simpson J.L., Bischoff F.Z. Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR. Ann. N.Y. Acad. Sci. 2006, 1075:230-234.
213. Kamat A.A., Bischoff F.Z., Dang D., Baldwin M.F., Han L.Y., Lin Y.G., et al. Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol. Ther. 2006, 5:1369-1374.
214. Lo Y.M., Chan K.C., Sun H., Chen E.Z., Jiang P., Lun F.M., et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci. Transl. Med. 2010, 2:61ra91.
215. Lo Y.M., Tsui N.B., Chiu R.W., Lau T.K., Leung T.N., Heung M.M., et al. Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection. Nat. Med. 2007, 13:218-223.
216. Lo Y.M., Lun F.M., Chan K.C., Tsui N.B., Chong K.C., Lau T.K., et al. Digital PCR for the molecular detection of fetal chromosomal aneuploidy. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:13116-13121.
217. Chiu R.W., Akolekar R., Zheng Y.W., Leung T.Y., Sun H., Chan K.C., et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 2011, 342:c7401.
218. Wu J., Matthaei H., Maitra A., Dal M.M., Wood L.D., Eshleman J.R., et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci. Transl. Med. 2011, 3:92ra66.
219. Harismendy O., Schwab R.B., Bao L., Olson J., Rozenzhak S., Kotsopoulos S.K., et al. Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing. Genome Biol. 2011, 12:R124.
220. Wagle N., Berger M.F., Davis M.J., Blumenstiel B., Defelice M., Pochanard P., et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012, 2:82-93.
221. Diamandis E.P. Cancer biomarkers: can we turn recent failures into success?. J. Natl. Cancer Inst. 2010, 102:1462-1467.